Tirzepatide improves markers of metabolic conditions including NASH

Eli Lilly presented data from several studies of tirzepatide, an investigational dual gastric inhibitory polypeptide and glucagonlike peptide1 receptor agonist, that showed its potential to treat metabolic conditions including type 2 diabetes and nonalcoholic steatohepatitis.

“We are excited about tirzepatide’s potential to make an important impact on people with type 2 diabetes and other conditions, including obesity and NASH,” Brad Woodward, MD, global development leader of incretins at Lilly, said in a press release. “The tirzepatide results seen in early and mid-stage trials pave the way for our extensive phase 3 programs, reinforce our commitment to researching it further across different populations and support its potential of addressing an unmet treatment need.”

From the phase 2 studies, tirzepatide improved markers of beta cell function and insulin sensitivity in patients with type 2 diabetes and consistent positive impact on blood glucose control (HbA1c reductions up to 2%) and weight loss (up to 5.7 kg) while improving tolerability with dose escalations.

Results from a subanalysis also showed that treatment with tirzepatide led to improvements in NASH-related markers.

Treatment-related adverse events were mild to moderate in intensity and overall less common than in previous studies. Discontinuation rates due to adverse events were less than 5% compared with placebo.

Reference: www.lilly.com

Eli Lilly presented data from several studies of tirzepatide, an investigational dual gastric inhibitory polypeptide and glucagonlike peptide1 receptor agonist, that showed its potential to treat metabolic conditions including type 2 diabetes and nonalcoholic steatohepatitis.

“We are excited about tirzepatide’s potential to make an important impact on people with type 2 diabetes and other conditions, including obesity and NASH,” Brad Woodward, MD, global development leader of incretins at Lilly, said in a press release. “The tirzepatide results seen in early and mid-stage trials pave the way for our extensive phase 3 programs, reinforce our commitment to researching it further across different populations and support its potential of addressing an unmet treatment need.”

From the phase 2 studies, tirzepatide improved markers of beta cell function and insulin sensitivity in patients with type 2 diabetes and consistent positive impact on blood glucose control (HbA1c reductions up to 2%) and weight loss (up to 5.7 kg) while improving tolerability with dose escalations.

Results from a subanalysis also showed that treatment with tirzepatide led to improvements in NASH-related markers.

Treatment-related adverse events were mild to moderate in intensity and overall less common than in previous studies. Discontinuation rates due to adverse events were less than 5% compared with placebo.

Reference: www.lilly.com